SEARCH

inest.uff.br

Provided by Alexa ranking, inest.uff.br has ranked N/A in N/A and 1269002nd on the world. It is hoted in N/A with IP address 200.20.0.121. The home page has 0 external link.

Top keyword related from Search Engine of inest.uff.br

• inestimable

• inest

• inestimable definition

• instagram

• iniesta

• investopedia

• inesthetic

• investing

• inestgrame

• cinestyle luts

• inestrocchia

• invest wine

• inestabilidad

• inestimable synonyme

• inestimability

• cinestar

• inestroza

• investment calculator

• inestimable worth

• inestabilidad emocional

• inest wine by martell holt

• inestimable significado

• inestable significado

• iniesta age

• iniesta movies

• iniesta 2010

• iniesta current club

• iniesta height

• iniesta barcelona

• iniesta fifa 23

• iniesta club

• iniesta stats

• iniesta number

• iniesta transfermarkt

• iniesta wikipedia

• iniesta retirement

• iniesta miami

• iniesta png

• iniesta marcatoons

• iniesta ballon d'or

• iniesta 2010 stats

• iniesta xavi

• iniesta vissel kobe

• iniesta sofifa

• iniesta academy

• iniesta footballer

Owner:	N/A
RANK:	1269002
Country code:	N/A
Country name:	N/A
Rank on country:	N/A
Host:	N/A
Ip:	200.20.0.121
Ref link:
Extension:	uff.br

Top URL related to inest.uff.br

• 1. BioNTech | The conception of our mRNA platforms

  biontech.com

  Link: https://www.biontech.com/int/en/home/pipeline-and-products/platforms/our-mrna-platforms.html

  Description: WEBWith our Individualized Neoantigen Specific Immunotherapy (iNeST) platform, we have developed a first-in-kind, on-demand manufacturing process for mRNA vaccines designed to target mutations that are unique to the patient’s specific cancer, so …

• 2. BioNTech Expands Clinical Oncology Portfolio with First

  globenewswire.com

  Link: https://www.globenewswire.com/news-release/2021/10/01/2306757/0/en/BioNTech-Expands-Clinical-Oncology-Portfolio-with-First-Patient-Dosed-in-Phase-2-Trial-of-mRNA-based-Individualized-Immunotherapy-BNT122-in-Colorectal-Cancer-Patients.html

  Description: WEBOctober 01, 2021 02:00 ET | Source: BioNTech SE. Follow. Second Phase 2 trial initiated from BioNTech’s proprietary individualized mRNA-based cancer vaccine platform iNeST. Randomized Phase 2 ...

• 3. BioNTech

  biontech.com

  Link: https://www.biontech.com/content/dam/corporate/pdf/BioNTech_INeST-Factsheet.pdf

  Description: WEBBioNTech has advanced iNeST in collaboration with its partner Genentech, a member of the Roche Group. The companies are investigating mRNA-based cancer therapies targeting neoantigens in clinical trials for the potential treatment of multiple cancers.

• 4. Indication-specific tumor evolution and its impact on neoantigen

  nih.gov

  Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488717/

  Description: WEBOct 1, 2021 · Individualized neoantigen-specific immunotherapy (iNeST) requires robustly expressed clonal neoantigens for efficacy, but tumor mutational heterogeneity, loss of neoantigen expression, and variable tissue sampling present challenges.

• 5. Positive Phase 1 Data from mRNA-based Individualized

  globenewswire.com

  Link: https://www.globenewswire.com/news-release/2022/06/05/2456347/0/en/Positive-Phase-1-Data-from-mRNA-based-Individualized-Neoantigen-Specific-Immunotherapy-in-Patients-with-Resected-Pancreatic-Cancer-presented-at-ASCO.html

  Description: WEBJun 5, 2022 · Autogene Cevumeran, a fully individualized mRNA cancer immunotherapy (iNeST) demonstrated that vaccine-induced immunity significantly correlates with delayed tumor recurrence in patients with ...

• 6. Microbial Control Strategy for iNeST mRNA a Cell-Free, …

  americanpharmaceuticalreview.com

  Link: https://www.americanpharmaceuticalreview.com/Featured-Articles/581702-Microbial-Control-Strategy-for-iNeST-mRNA-a-Cell-Free-Individualized-ATMP/

  Description: WEBDec 1, 2021 · The following paper describes a cell-free iNeST-mRNA process and the microbial controls in place to ensure microbially safe manufacturing for ongoing clinical trials. iNeST mRNA Project Introduction. The iNeST mRNA immunotherapy project is a partnership between Roche-Genentech and BioNTech.

• 7. Personalized RNA neoantigen vaccines stimulate T cells in

  nature.com

  Link: https://www.nature.com/articles/s41586-023-06063-y

  Description: WEBMay 10, 2023 · A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell ...

• 8. Neoantigen personalized vaccine plus anti-PD-1 antibody in …

  nih.gov

  Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843347/

  Description: WEBOct 8, 2022 · The study from Ott et al. published last year in Cell ( 3) demonstrated the safety of treating advanced cancer patients with the long-peptide neoantigen vaccine NEO-PV-01 in combination with the anti PD-1 antibody nivolumab. The primary end point of this phase 1b study was achieved, demonstrating the safety of the combination with no …

• 9. Individualised mRNA vaccine shows promise in pancreatic …

  europeanpharmaceuticalreview.com

  Link: https://www.europeanpharmaceuticalreview.com/news/172008/biontech-results-inest-pdac-treatment/

  Description: WEBJun 8, 2022 · Phase I study shows that mRNA-based individualised neoantigen specific immunotherapy (iNeST) vaccines can be used to stimulate T cells to recognise neoantigens in pancreatic cancer patients. BioNTech has announced initial data from an ongoing investigator-initiated first-in-human Phase I study evaluating the safety and …

• 10. iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell …

  targetedonc.com

  Link: https://www.targetedonc.com/view/inest-atezolizumab-combo-induces-neoantigen-specific-t-cell-responses-in-advanced-solid-tumors

  Description: WEBJun 22, 2020 · A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumabin patients with locally advanced or metastatic solid tumors. Presented at: 2020 AACR Virtual Annual Meeting II, June 22-24, 2020; Virtual.